Table 1.
Adverse effects profile of Itolizumab
| Common adverse effects encountered | Anand et al25 n=40(moderate–severe psoriasis) |
Krupashankar et al26 n=225/52 weeks (moderate–severe psoriasis) |
Rodriguez et al16 n=15/24 weeks (rheumatoid arthritis) |
|---|---|---|---|
| Infusion-related reaction | Chills, 5.69% Pyrexia, 4.88% |
Acute, 17% Delayed, 3.6% Pyrexia, 8.5% |
Headache, 73% Pyrexia, 60% Nausea, 46% |
| Pyrexia due to infections | ND | 1.3% URTI, 7.6% |
UTI, three patients |
| Pruritus | ND | 5.4% | 40% |
| Anti-drug antibody | One patient tested positive | 15.7% no effect on safety and efficacy of drug | Transient and low levels |
| Effect on blood cells | ND | Small and transient decrease in mean absolute lymphocyte count | WBC count and absolute lymphocyte count within normal limits |
Abbreviations: ND, no data; URTI, upper respiratory tract infection; UTI, urinary tract infection; WBC, white blood cell.